Results of a phase I and phase II trial on a new human vaccine against the deadly H5N1 bird flu virus that is made from cell culture instead of embryonated eggs (making it faster and cheaper to produce) show that it is safe and effective against a number of divergent strains.

See also: A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture, New England Journal of Medicine